Illumina's "impressive" Q1 resurrects Roche rumours
This article was originally published in Clinica
Illumina beat analyst estimates in its first fiscal quarter with revenues of $331.0 million (+21%) and non-GAAP earnings of $0.46 per diluted share, ahead of consensus forecasts of $312 million revenue and $0.39-per-share earnings. The Q1 performance, described by analysts as “strong” and “impressive”, raises the possibility of another bid by long-time admirer Roche, which tried and failed to buy Illumina last year. But if Roche does re-enter the fray, it may need to raise its offer, which previously stood at $51 per share, or $6.7 billion in total, and which Illumina rejected as inadequate (www.clinica.co.uk, 19 April 2012).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.